Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore

Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug.

24/7 Wall Street • 20 hours ago

Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

Zacks Investment Research • 20 hours ago

MDT vs. A: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Agilent Technologies (A). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Aug 18, 2026

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

Business Wire • Jul 29, 2026

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.

Business Wire • Jul 28, 2026

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

Business Wire • Jul 23, 2026

Agilent Increases Its Investment in HALO X-ray Technologies

NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.

Business Wire • Jul 20, 2026

Dividend Champion, Contender, And Challenger Highlights: Week Of July 19

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

Seeking Alpha • Jul 18, 2026

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

Business Wire • Jul 14, 2026

Agilent Strengthens Biopharma Growth Prospects With AI Expansion

A enhances AI-powered lab software, automation and digital workflows to support drug discovery, biopharma research and long-term growth.

Zacks Investment Research • Jul 9, 2026